Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses: 2011-2021

Historic Other Accumulated Expenses for Neurocrine Biosciences (NBIX) over the last 4 years, with Sep 2021 value amounting to $20.0 million.

  • Neurocrine Biosciences' Other Accumulated Expenses rose 29.03% to $20.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $20.0 million, marking a year-over-year increase of 29.03%. This contributed to the annual value of $17.8 million for FY2020, which is 17.11% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Other Accumulated Expenses of $20.0 million as of Q3 2021, which was down 9.09% from $22.0 million recorded in Q2 2021.
  • Neurocrine Biosciences' Other Accumulated Expenses' 5-year high stood at $22.0 million during Q2 2021, with a 5-year trough of $85,000 in Q1 2018.
  • For the 3-year period, Neurocrine Biosciences' Other Accumulated Expenses averaged around $14.7 million, with its median value being $15.5 million (2020).
  • In the last 5 years, Neurocrine Biosciences' Other Accumulated Expenses plummeted by 89.79% in 2018 and then skyrocketed by 4,280.00% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' Other Accumulated Expenses (Quarterly) stood at $18.2 million in 2017, then plummeted by 89.79% to $1.9 million in 2018, then soared by 718.97% to $15.2 million in 2019, then increased by 17.11% to $17.8 million in 2020, then rose by 29.03% to $20.0 million in 2021.
  • Its last three reported values are $20.0 million in Q3 2021, $22.0 million for Q2 2021, and $18.1 million during Q1 2021.